If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFevertree Regulatory News (FEVR)

Share Price Information for Fevertree (FEVR)

Share Price is delayed by 15 minutes
Get Live Data
806.00    -11.50 (-1.41%)
Bid:
810.00
Ask:
811.50
Spread: 1.50 (0.185%)
Market Cap: £914.44m
FEVR Live PriceLast checked at - London Stock Exchange

Intraday Fevertree Share Chart

Pre-close trading update

29 Jan 2026 07:00

RNS Number : 8094Q
Fevertree Drinks PLC
29 January 2026
 

Fever-Tree Drinks plc

"Excellent strategic progress in 2025 and expect to deliver a financial performance

marginally ahead of market expectations."

 

Fever-Tree Drinks plc (the "Group"), the world's leading supplier of premium carbonated mixers, today provides a pre-close trading update for the year ended 31 December 2025.

 

Adjusted revenue1 and adjusted EBITDA2 for FY25 are expected to be marginally ahead of current market expectations3, based upon good momentum in the second half which has resulted in Fever-Tree brand revenue increasing by 5% in H2, and full year growth of 4% (both at constant currency). This reflects continued delivery against the Group's strategic priorities and ongoing strong market share performance. In the US, the transition into Molson Coors' national distribution network is progressing to plan and, alongside an upweighted marketing investment, will provide a strong platform for 2026.

 

Following the £100m share buyback programme undertaken during 2025, the previously announced additional £30m share buyback tranche will commence in February 2026.

 

£m

FY25

£m

FY24

£m

% change

 

% change (CC)*

US

131.9

128.0

3%

6%

UK

108.4

111.1

(2%)

Europe Fever-Tree brand revenue

94.7

92.7

2%

2%

ROW

37.7

32.2

17%

22%

Total Adjusted Fever-Tree Revenue1

372.7

364.0

2%

4%

GDP brand revenue

2.6

4.5

(42%)

(43%)

Total Adjusted Revenue

375.3

368.5

2%

3%

*Constant Currency (CC).1. Adjusted Revenue is statutory reported revenue adjusted to bring US revenue in line with invoiced sales to customers.2. Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation, share-based payment charges, exceptional items and finance costs. As disclosed in September 2025, the Company has not provided for certain costs related to UK Extended Producer Responsibility levy, and continues to engage with the Environment Agency on the same.3. Company collated consensus FY25 adjusted revenue £372.4m and adjusted EBITDA £44.4m. FY26 adjusted revenue consensus £409.4m (current range £392.4m to £429.0m)) and adjusted EBITDA consensus £49.9m (current range £43.7m to £53.8m)

2025 Highlights:

· US revenue +6%*. The integration of Fever-Tree into Molson Coors' national network of distributors has progressed well through the year, with continued positive brand momentum.

· UK revenue -2%. Trading notably improved in the second half, driven by a robust Off-Trade performance with increasing momentum across the Group's portfolio beyond tonic, particularly our premium soft drink range.

· Europe revenue +2%*. Growth was led by a strong performance in France and Benelux, as the Group continued to execute its strategy across the region.

· ROW +22%* reflecting particularly strong growth in Australia, New Zealand and Canada as well as some beneficial phasing of orders.

 

Outlook

We remain comfortable with current 2026 market expectations.

Tim Warrillow, CEO of Fever-Tree commented:

"We made excellent progress in 2025. Our partnership with Molson Coors in the US is progressing well, and the momentum behind the brand is especially encouraging, giving us confidence in the growing opportunity in our largest market as execution moves beyond the transition phase.

Across all our markets, we are continuing to build momentum as we broaden Fever-Tree beyond tonic, positioning the brand as not only the premium mixer but also premium soft drink of choice. We are uniquely positioned to unlock the growth opportunities afforded by the consumer trends towards moderation, premiumisation and longer, lighter serves. With exciting marketing campaigns and a strong innovation pipeline, delivered by our passionate team, I am confident we will drive strong growth in 2026 and beyond."

Next Scheduled Announcement

The Group will announce its Preliminary Results on 24 March 2026.

 

For more information please contact:

Investor queries

Steve Nightingale, Investor Relations Director I steve.nightingale@fever-tree.com I +44 (0)7951 849 564

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024

 

Nominated Advisor and Broker - Investec Bank plc

David Flin I +44 (0)20 7597 5970

Corporate Broker - Jefferies International Limited

Ed Matthews I +44 (0)20 7029 8000

Financial PR advisers - FGS Global

Faeth Birch +44 (0)7768 943 171; Anjali Unnikrishnan +44 (0) 7826 534 233

 

 

Notes to the Editors:

Fever-Tree is the world's leading supplier of premium carbonated mixers by retail sales value, with distribution to over 95 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers and soft drinks to hotels, restaurants, bars and cafes ("On Trade") as well as a broad range of retail outlets ("Off Trade").

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLALRITFIR
Date   Source Headline
11th Sep 20257:00 amRNSTransaction in Own Shares
10th Sep 20257:00 amRNSTransaction in Own Shares
9th Sep 20257:00 amRNSTransaction in Own Shares
8th Sep 20255:08 pmRNSHolding(s) in Company
8th Sep 20257:00 amRNSTransaction in Own Shares
5th Sep 20257:00 amRNSTransaction in Own Shares
4th Sep 20257:00 amRNSTransaction in Own Shares
3rd Sep 20257:00 amRNSTransaction in Own Shares
2nd Sep 20257:00 amRNSTransaction in Own Shares
1st Sep 20257:00 amRNSTotal Voting Rights
1st Sep 20257:00 amRNSTransaction in Own Shares
29th Aug 20257:00 amRNSTransaction in Own Shares
28th Aug 20257:00 amRNSTransaction in Own Shares
27th Aug 20257:00 amRNSTransaction in Own Shares
26th Aug 20257:00 amRNSTransaction in Own Shares
22nd Aug 20257:00 amRNSTransaction in Own Shares
21st Aug 20257:00 amRNSTransaction in Own Shares
20th Aug 20257:00 amRNSTransaction in Own Shares
19th Aug 20257:00 amRNSTransaction in Own Shares
18th Aug 20257:00 amRNSTransaction in Own Shares
15th Aug 20257:00 amRNSTransaction in Own Shares
14th Aug 20257:00 amRNSTransaction in Own Shares
13th Aug 20257:00 amRNSTransaction in Own Shares
12th Aug 20257:00 amRNSTransaction in Own Shares
11th Aug 20257:00 amRNSTransaction in Own Shares
8th Aug 20257:00 amRNSTransaction in Own Shares
7th Aug 20257:00 amRNSTransaction in Own Shares
6th Aug 20257:00 amRNSTransaction in Own Shares
5th Aug 20257:00 amRNSTransaction in Own Shares
4th Aug 20257:00 amRNSTransaction in Own Shares
1st Aug 20257:00 amRNSTotal Voting Rights
1st Aug 20257:00 amRNSTransaction in Own Shares
31st Jul 20257:00 amRNSTransaction in Own Shares
30th Jul 20257:00 amRNSTransaction in Own Shares
29th Jul 20257:00 amRNSTransaction in Own Shares
28th Jul 20257:00 amRNSTransaction in Own Shares
25th Jul 20257:00 amRNSTransaction in Own Shares
24th Jul 20257:00 amRNSTransaction in Own Shares
23rd Jul 20257:00 amRNSTransaction in Own Shares
22nd Jul 20257:00 amRNSTransaction in Own Shares
21st Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20257:00 amRNSTransaction in Own Shares
17th Jul 20257:00 amRNSTransaction in Own Shares
16th Jul 20257:00 amRNSTransaction in Own Shares
15th Jul 20257:00 amRNSTransaction in Own Shares
14th Jul 20257:00 amRNSTransaction in Own Shares
11th Jul 20257:00 amRNSTransaction in Own Shares
10th Jul 20257:00 amRNSTransaction in Own Shares
9th Jul 20257:00 amRNSTransaction in Own Shares
8th Jul 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.